Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia

Leukemia

Volumn 29, Issue 9, 2015, Pages 1891-1900

  Ruggeri, A ^a,b,c   Labopin, M ^a   Sanz, G ^d   Piemontese, S ^e   Arcese, W ^f   Bacigalupo, A ^g   Blaise, D ^h   Bosi, A ⁱ   Huang, H ^j   Karakasis, D ^k   Koc, Y ^l   Michallet, M ^m   Picardi, A ^f   Sanz, J ^d   Santarone, S ⁿ   Sengelov, H ^o   Sierra, J ^p   Vincent, L ^q   Volt, F ^c   Nagler, A ^a,r   Gluckman, E ^c,s   Ciceri, F ^e   Rocha, V ^c,t   Mohty, M ^a,b   more..

^a HÔPITAL SAINT ANTOINE   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^k EVANGELISMOS HOSPITAL   (Greece)

^l Medicalpark Antalya Hospital Pediatric Stem Cell Transplantation Unit   (Turkey)

^m EDOUARD HERRIOT HOSPITAL   (France)

ⁿ Ospedale Civile   (Italy)

^o University of Copenhagen   (Denmark)

^p UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^q MONTPELLIER UNIVERSITY HOSPITAL   (France)

^r SHEBA MEDICAL CENTER   (Israel)

^s CENTRE SCIENTIFIQUE DE MONACO   (Monaco)

^t UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; INTERLEUKIN 2 RECEPTOR ALPHA; MELPHALAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN; HLA ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CONVALESCENCE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNRELATED CORD BLOOD TRANSPLANTATION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940788821     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.98     Document Type: Article

References (40)

1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
2. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol 2010; 150: 389-405.
3. Patriarca F, Luznik L, Medeot M, Zecca M, Bacigalupo A, Di Bartolomeo P et al. Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol 2014; 93: 187-197.
4. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-2285.
5. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653-660.
6. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275.
7. Ballen KK, Spitzer TR. The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant 2011; 46: 323-329.
8. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343-1347.
9. Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2013; 121: 752-758.
10. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110: 3064-3070.
11. Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia 2014; 28: 779-786.
12. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653-660.
13. Brunstein CG, Eapen M, Ahn KW, Appelbaum FR, Ballen KK, Champlin RE et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012; 119: 5591-5598.
14. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C et al. Successful engraftment of T-cell-depleted haploidentical 'three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
15. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
16. Champlin R, Hesdorffer C, Lowenberg B, Martelli MF, Mertelsmann RH, Reisner Y et al. Haploidentical 'megadose' stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings. Leukemia 2002; 16: 427-428.
17. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK et al. T-cellreplete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31: 1310-1316.
18. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLAidentical siblings. J Clin Oncol 1997; 15: 1767-1777.
19. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
20. Terwey TH, Vega-Ruiz A, Hemmati PG, Martus P, Dietz E, le Coutre P et al. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia 2012; 26: 536-542.
21. Kaplan. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Cox. Regression models and life tables. J R Stat Soc 1972; 34: 187.
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
24. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118: 282-288.
25. Labopin M, Ruggeri A, Gorin NC, Gluckman E, Blaise D, Mannone L et al. Costeffectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France. Haematologica 2014; 99: 535-540.
26. Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood 2014; 123: 133-140.
27. Gutman JA, Riddell SR, McGoldrick S, Delaney C. Double unit cord blood transplantation: who wins-and why do we care? Chimerism 2010; 1: 21-22.
28. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M et al. Cordblood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367: 2305-2315.
29. Farag SS, Srivastava S, Messina-Graham S, Schwartz J, Robertson MJ, Abonour R et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev 2013; 22: 1007-1015.
30. Ji SQ, Chen HR, Wang HX, Yan HM, Zhu L, Liu J et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002; 30: 861-866.
31. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/ haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065-3073.
32. Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R et al. Highdose cyclophosphamide as single-agent, short-course prophylaxis of graft-versushost disease. Blood 2010; 115: 3224-3230.
33. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117-122.
34. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849-857.
35. Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2014; 29: 396-405.
36. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Peripheralblood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496.
37. Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 2005; 90: 643-648.
38. Labopin M, Gorin NC, Polge E, Socie G, Gurman G, Gluckman E et al. A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. Bone Marrow Transplant 2014; 49: 376-381.
39. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010; 115: 3437-3446.
40. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574-3581.